FI3848028T3 - Okulaaristen sairauksien hoitomenetelmiä - Google Patents
Okulaaristen sairauksien hoitomenetelmiä Download PDFInfo
- Publication number
- FI3848028T3 FI3848028T3 FIEP20212556.3T FI20212556T FI3848028T3 FI 3848028 T3 FI3848028 T3 FI 3848028T3 FI 20212556 T FI20212556 T FI 20212556T FI 3848028 T3 FI3848028 T3 FI 3848028T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical formulation
- combination
- varenicline
- pharmaceutically acceptable
- micrograms
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims 12
- 229960004751 varenicline Drugs 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 102100026607 ALS2 C-terminal-like protein Human genes 0.000 claims 1
- 102100034719 Extracellular glycoprotein lacritin Human genes 0.000 claims 1
- 101000717960 Homo sapiens ALS2 C-terminal-like protein Proteins 0.000 claims 1
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims 1
- 101001090521 Homo sapiens Extracellular glycoprotein lacritin Proteins 0.000 claims 1
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims 1
- 101001067189 Homo sapiens Plexin-A1 Proteins 0.000 claims 1
- 101000731732 Homo sapiens Rho guanine nucleotide exchange factor 19 Proteins 0.000 claims 1
- 101000650148 Homo sapiens WD repeat domain phosphoinositide-interacting protein 1 Proteins 0.000 claims 1
- 101000915475 Homo sapiens Zinc finger MIZ domain-containing protein 2 Proteins 0.000 claims 1
- 101710024993 KIAA1109 Proteins 0.000 claims 1
- 108010063045 Lactoferrin Proteins 0.000 claims 1
- 102100032241 Lactotransferrin Human genes 0.000 claims 1
- 108010022337 Leucine Enkephalin Proteins 0.000 claims 1
- 102100035196 POLG alternative reading frame Human genes 0.000 claims 1
- 102100034382 Plexin-A1 Human genes 0.000 claims 1
- 102000003946 Prolactin Human genes 0.000 claims 1
- 108010057464 Prolactin Proteins 0.000 claims 1
- 102100032433 Rho guanine nucleotide exchange factor 19 Human genes 0.000 claims 1
- 102100025378 Transmembrane protein KIAA1109 Human genes 0.000 claims 1
- 102100027543 WD repeat domain phosphoinositide-interacting protein 1 Human genes 0.000 claims 1
- 102100028536 Zinc finger MIZ domain-containing protein 2 Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 1
- 229940078795 lactoferrin Drugs 0.000 claims 1
- 235000021242 lactoferrin Nutrition 0.000 claims 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 229940097325 prolactin Drugs 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066280P | 2014-10-20 | 2014-10-20 | |
| US201562100844P | 2015-01-07 | 2015-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3848028T3 true FI3848028T3 (fi) | 2024-08-21 |
Family
ID=55748136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20212556.3T FI3848028T3 (fi) | 2014-10-20 | 2015-10-19 | Okulaaristen sairauksien hoitomenetelmiä |
Country Status (21)
| Country | Link |
|---|---|
| US (14) | US9504645B2 (enExample) |
| EP (3) | EP3209295B2 (enExample) |
| JP (3) | JP6873906B2 (enExample) |
| KR (2) | KR102601505B1 (enExample) |
| CN (3) | CN107106542B (enExample) |
| AU (2) | AU2015336216B2 (enExample) |
| BR (2) | BR122022025737B1 (enExample) |
| CA (1) | CA2965129C (enExample) |
| DK (2) | DK3209295T4 (enExample) |
| EA (1) | EA035335B1 (enExample) |
| ES (2) | ES2848977T5 (enExample) |
| FI (1) | FI3848028T3 (enExample) |
| IL (3) | IL293188B2 (enExample) |
| MX (2) | MX392383B (enExample) |
| MY (1) | MY186870A (enExample) |
| PH (1) | PH12017500602A1 (enExample) |
| PL (1) | PL3848028T3 (enExample) |
| PT (2) | PT3209295T (enExample) |
| SG (2) | SG10202011669PA (enExample) |
| WO (1) | WO2016064759A1 (enExample) |
| ZA (1) | ZA201703467B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| NZ746468A (en) * | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| WO2020014217A1 (en) * | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| EP4142734B1 (en) | 2020-04-28 | 2025-08-20 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| JP2024517459A (ja) * | 2021-05-07 | 2024-04-22 | オイスター ポイント ファーマ インコーポレイテッド | ベクター及びニコチン作動薬の併用療法 |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
| DE102023208057A1 (de) * | 2023-08-23 | 2025-02-27 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| IL161326A0 (en) | 2001-11-29 | 2004-09-27 | Pfizer Prod Inc | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| AU2003269413A1 (en) * | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| EP1802276A1 (en) * | 2004-10-15 | 2007-07-04 | Pfizer Products Inc. | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| CA2578176C (en) * | 2004-11-09 | 2013-09-24 | Novagali Pharma Sa | Ophthalmic emulsions containing an immunosuppressive agent |
| US20090023819A1 (en) * | 2005-03-22 | 2009-01-22 | Anders Axelsson | Use of an Artificial Sweetener to Enhance Absorption of Nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| JP5276982B2 (ja) | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
| JP5505760B2 (ja) | 2005-09-27 | 2014-05-28 | ティッシュテク・インコーポレーテッド | 羊膜調製物及び精製組成物及びその使用方法 |
| TWI405763B (zh) | 2006-11-02 | 2013-08-21 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| DK2114970T3 (da) * | 2007-02-02 | 2011-09-19 | Pfizer Prod Inc | Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer |
| EP1977746B8 (en) * | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US20090215787A1 (en) | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| US20110071180A1 (en) | 2008-03-05 | 2011-03-24 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| JP2012502039A (ja) | 2008-09-05 | 2012-01-26 | ターガセプト，インコーポレイテッド | ジアザビシクロオクタンのアミド及びその用途 |
| IL266097B (en) | 2008-12-01 | 2022-07-01 | Oyster Point Pharma Inc | Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| US20140170157A1 (en) * | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| CN103619354A (zh) * | 2011-06-30 | 2014-03-05 | 东丽株式会社 | 止痒剂 |
| IN2014CN03647A (enExample) * | 2011-10-20 | 2015-10-09 | Novartis Ag | |
| US20140357971A1 (en) * | 2011-11-30 | 2014-12-04 | Diagnostear Ltd. | Dry eye diagnostic |
| ES2426517B1 (es) * | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
| EP2968368B1 (en) | 2013-03-15 | 2017-08-09 | Glia LLC | Cranial delivery of pharmaceuticals |
| CN108744272A (zh) | 2013-04-19 | 2018-11-06 | 奥库利维公司 | 鼻刺激装置和方法 |
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| NZ746468A (en) | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| WO2020014217A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| US20240173381A1 (en) | 2021-03-03 | 2024-05-30 | Kagoshima University | Hb-egf gene therapy for diabetes |
-
2015
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/zh active Active
- 2015-10-19 EA EA201790893A patent/EA035335B1/ru unknown
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 MX MX2017005064A patent/MX392383B/es unknown
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/pt active IP Right Grant
- 2015-10-19 PL PL20212556.3T patent/PL3848028T3/pl unknown
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 PT PT158523407T patent/PT3209295T/pt unknown
- 2015-10-19 IL IL293188A patent/IL293188B2/en unknown
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/ko active Active
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/da active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
- 2015-10-19 IL IL318427A patent/IL318427A/en unknown
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/ko active Active
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/ja active Active
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 DK DK20212556.3T patent/DK3848028T5/da active
- 2015-10-19 FI FIEP20212556.3T patent/FI3848028T3/fi active
- 2015-10-19 ES ES15852340T patent/ES2848977T5/es active Active
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 CN CN202010304809.9A patent/CN111956650B/zh active Active
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 ES ES20212556T patent/ES2986830T3/es active Active
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en not_active Ceased
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 PT PT202125563T patent/PT3848028T/pt unknown
- 2015-10-19 CN CN202010304375.2A patent/CN111956803B/zh active Active
- 2015-10-19 EP EP24171017.7A patent/EP4413974A3/en active Pending
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/pt active IP Right Grant
- 2015-10-19 EP EP20212556.3A patent/EP3848028B9/en active Active
-
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/es unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
-
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
-
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/ja active Active
-
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
-
2022
- 2022-12-20 JP JP2022202809A patent/JP7502404B2/ja active Active
-
2023
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
-
2024
- 2024-01-26 US US18/423,908 patent/US20240173318A1/en not_active Abandoned
-
2025
- 2025-04-03 US US19/169,843 patent/US12576080B2/en active Active
- 2025-04-03 US US19/169,836 patent/US12653824B2/en active Active
- 2025-04-03 US US19/169,817 patent/US20250235449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reimondez-Troitiño et al. | Nanotherapies for the treatment of ocular diseases | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| SA520411119B1 (ar) | تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها | |
| PH12017500479A1 (en) | Liquid inhalation formulation comprising prl554 | |
| IL293188B1 (en) | Varenicline compound for use as a medication for treating dry eye, increasing tear production and treating eye discomfort and a pramipexole preparation containing varenicline | |
| WO2014012069A3 (en) | Dry powder drug delivery systems and methods | |
| WO2013155201A3 (en) | Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration | |
| MX389346B (es) | Formulaciones de anticuerpos monoclonales de alta concentración. | |
| EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
| JP2016539921A5 (enExample) | ||
| RU2739037C3 (ru) | Композиция для контролируемой стимуляции яичников | |
| BR112013020005A2 (pt) | peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica | |
| JP2013520405A5 (enExample) | ||
| BR112014008602A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica | |
| IL290069B2 (en) | Methods for treating eye conditions | |
| AU2015242791A1 (en) | Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| WO2005084638A3 (en) | Formulations decreasing infectivity of pulmonary diseases | |
| Buttini et al. | Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients | |
| RU2010133870A (ru) | Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций | |
| JP2019513759A5 (enExample) | ||
| JP2017531044A5 (enExample) | ||
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| RU2014130894A (ru) | Пептид, обладающий нейропротекторной и ноотропной активностью, и фармацевтическая композиция на его основе | |
| WO2018065917A3 (en) | A synthetic pulmonary surfactant composition for treating lung conditions |